News|Articles|January 29, 2024
Failing to plan is planning to fail: the case for early use of cGMP raw materials
Author(s)Avantor
Knowing the right time to introduce cGMP raw materials when scaling up mAbs manufacturing avoids production process redevelopment, delays and increased costs. Using cGMP grade reagents earlier makes for a seamless transition while maintaining quality and viability. Learn key considerations for a seamless scale up process in our GMP fact sheet.
Newsletter
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.
Related Content
Trending on Pharmaceutical Technology
1
European Parliament Revamps Pharmaceutical Policy Framework
2
EMA Calls New EU Pharma Legislation Most Significant in Two Decades
3
Tjoapack’s Advanced Packaging Expansion Aims to Meet Rising Demand
4
Regulatory Expectations for Evaluating GMP Facilities and Equipment
5
